Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

25. November 2025 08:00 ET | Quelle: Compass Therapeutics

Compass Therapeutics to Participate in Upcoming December Investor Events

BOSTON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics,...
05. November 2025 07:30 ET | Quelle: Compass Therapeutics

Compass Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Based on a continuing trend of decreased mortality in the ongoing Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer (BTC),...
04. November 2025 09:00 ET | Quelle: Compass Therapeutics

Compass Therapeutics Presents Preclinical Data on CTX-10726, a Differentiated PD-1 x VEGF-A Bispecific Antibody, at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting

CTX-10726 demonstrated potent, simultaneous inhibition of tumor angiogenesis and PD-1-mediated immune suppression, and eliminated tumors in multiple preclinical studies.In vivo, CTX-10726 outperformed...
03. November 2025 08:00 ET | Quelle: Compass Therapeutics

Compass Therapeutics to Participate in Upcoming November Investor Events

BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based...
26. August 2025 08:00 ET | Quelle: Compass Therapeutics

Compass Therapeutics to Participate in Upcoming September Investor Events

BOSTON, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based...
12. August 2025 22:28 ET | Quelle: Compass Therapeutics

Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering

BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based...
12. August 2025 16:01 ET | Quelle: Compass Therapeutics

Compass Therapeutics Announces Proposed Public Offering

BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based...
11. August 2025 07:00 ET | Quelle: Compass Therapeutics

Compass Therapeutics Reports 2025 Second Quarter Financial Results and Provides Corporate Update

In the ongoing Phase 2/3 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer, fewer deaths have been observed than originally projected. We believe...
08. August 2025 16:01 ET | Quelle: Compass Therapeutics

Compass Therapeutics to Present Second Quarter Financial Results and Provide Business Update on August 11, 2025

BOSTON, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics,...
28. Mai 2025 08:00 ET | Quelle: Compass Therapeutics

Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference

BOSTON, May 28, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics,...

Nächste Seite